| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 110 | 2023 | 396 | 23.210 |
Why?
|
| Stroke Volume | 43 | 2022 | 100 | 5.550 |
Why?
|
| Hospitalization | 54 | 2022 | 810 | 5.360 |
Why?
|
| Humans | 136 | 2023 | 17822 | 2.870 |
Why?
|
| Natriuretic Peptide, Brain | 16 | 2022 | 27 | 2.760 |
Why?
|
| Angiotensin Receptor Antagonists | 12 | 2022 | 53 | 2.540 |
Why?
|
| Neprilysin | 6 | 2020 | 10 | 2.390 |
Why?
|
| Benzazepines | 13 | 2016 | 24 | 2.150 |
Why?
|
| Aged | 68 | 2022 | 6173 | 2.140 |
Why?
|
| Digoxin | 5 | 2022 | 12 | 2.140 |
Why?
|
| Aminobutyrates | 10 | 2020 | 18 | 2.090 |
Why?
|
| Acute Disease | 16 | 2023 | 144 | 1.960 |
Why?
|
| Tetrazoles | 10 | 2020 | 15 | 1.950 |
Why?
|
| Male | 77 | 2022 | 10145 | 1.880 |
Why?
|
| Female | 82 | 2022 | 12780 | 1.790 |
Why?
|
| Registries | 14 | 2022 | 472 | 1.760 |
Why?
|
| Treatment Outcome | 37 | 2022 | 1265 | 1.700 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 10 | 2016 | 11 | 1.590 |
Why?
|
| Ventricular Function, Left | 11 | 2022 | 51 | 1.560 |
Why?
|
| Middle Aged | 55 | 2022 | 8020 | 1.540 |
Why?
|
| Prognosis | 31 | 2021 | 609 | 1.450 |
Why?
|
| Cardiovascular Diseases | 3 | 2021 | 599 | 1.410 |
Why?
|
| Atherosclerosis | 2 | 2021 | 53 | 1.400 |
Why?
|
| Patient Readmission | 11 | 2020 | 164 | 1.360 |
Why?
|
| Peptide Fragments | 9 | 2020 | 27 | 1.340 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 9 | 2022 | 86 | 1.330 |
Why?
|
| Disease Progression | 12 | 2022 | 267 | 1.310 |
Why?
|
| Inpatients | 7 | 2018 | 81 | 1.210 |
Why?
|
| Health Status | 5 | 2020 | 299 | 1.180 |
Why?
|
| Exercise Therapy | 2 | 2018 | 71 | 1.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2021 | 172 | 1.050 |
Why?
|
| Cardiotonic Agents | 7 | 2020 | 12 | 1.030 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2022 | 537 | 1.030 |
Why?
|
| Quality of Life | 7 | 2022 | 511 | 1.010 |
Why?
|
| Dyspnea | 6 | 2020 | 48 | 0.940 |
Why?
|
| Renin-Angiotensin System | 3 | 2022 | 17 | 0.930 |
Why?
|
| Prospective Studies | 20 | 2021 | 1286 | 0.910 |
Why?
|
| Anemia | 3 | 2020 | 34 | 0.890 |
Why?
|
| Patient Discharge | 8 | 2022 | 154 | 0.880 |
Why?
|
| Liver Diseases | 2 | 2015 | 23 | 0.870 |
Why?
|
| Double-Blind Method | 16 | 2020 | 160 | 0.850 |
Why?
|
| Drug Combinations | 8 | 2020 | 43 | 0.840 |
Why?
|
| Valsartan | 5 | 2020 | 11 | 0.840 |
Why?
|
| Randomized Controlled Trials as Topic | 14 | 2021 | 329 | 0.830 |
Why?
|
| Practice Guidelines as Topic | 4 | 2018 | 321 | 0.820 |
Why?
|
| Evidence-Based Medicine | 4 | 2017 | 186 | 0.820 |
Why?
|
| Thirst | 1 | 2022 | 1 | 0.820 |
Why?
|
| Forecasting | 2 | 2021 | 75 | 0.810 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2020 | 35 | 0.800 |
Why?
|
| Aged, 80 and over | 13 | 2022 | 1931 | 0.770 |
Why?
|
| Enalapril | 6 | 2020 | 8 | 0.760 |
Why?
|
| Clinical Trials as Topic | 5 | 2016 | 132 | 0.740 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2021 | 9 | 0.730 |
Why?
|
| Natriuretic Agents | 3 | 2017 | 3 | 0.730 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2021 | 24 | 0.720 |
Why?
|
| Natural Language Processing | 1 | 2021 | 58 | 0.720 |
Why?
|
| Global Health | 5 | 2017 | 33 | 0.710 |
Why?
|
| Exercise Tolerance | 1 | 2020 | 13 | 0.700 |
Why?
|
| Survival Rate | 14 | 2020 | 260 | 0.700 |
Why?
|
| Risk Factors | 22 | 2022 | 3362 | 0.690 |
Why?
|
| Pandemics | 6 | 2022 | 287 | 0.690 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2020 | 7 | 0.690 |
Why?
|
| Risk Assessment | 8 | 2020 | 1103 | 0.670 |
Why?
|
| United States | 20 | 2023 | 4007 | 0.640 |
Why?
|
| Retrospective Studies | 15 | 2022 | 2467 | 0.630 |
Why?
|
| Network Meta-Analysis | 1 | 2018 | 3 | 0.610 |
Why?
|
| Liver Function Tests | 2 | 2015 | 6 | 0.580 |
Why?
|
| Weight Loss | 2 | 2018 | 305 | 0.580 |
Why?
|
| Follow-Up Studies | 16 | 2021 | 1219 | 0.570 |
Why?
|
| Cause of Death | 9 | 2018 | 181 | 0.570 |
Why?
|
| Substance-Related Disorders | 5 | 2018 | 434 | 0.560 |
Why?
|
| Research Design | 3 | 2021 | 376 | 0.560 |
Why?
|
| Diuretics | 4 | 2022 | 17 | 0.560 |
Why?
|
| Glomerular Filtration Rate | 7 | 2022 | 154 | 0.560 |
Why?
|
| Outpatients | 1 | 2018 | 110 | 0.550 |
Why?
|
| Exercise | 2 | 2020 | 495 | 0.540 |
Why?
|
| Time Factors | 13 | 2020 | 1097 | 0.530 |
Why?
|
| Aspartate Aminotransferases | 2 | 2013 | 13 | 0.530 |
Why?
|
| Alanine Transaminase | 2 | 2013 | 22 | 0.530 |
Why?
|
| Predictive Value of Tests | 8 | 2020 | 354 | 0.510 |
Why?
|
| Blood Pressure | 4 | 2014 | 303 | 0.510 |
Why?
|
| Patient Admission | 5 | 2021 | 72 | 0.510 |
Why?
|
| Defibrillators, Implantable | 4 | 2020 | 32 | 0.500 |
Why?
|
| Weight Gain | 1 | 2017 | 173 | 0.490 |
Why?
|
| Hyponatremia | 2 | 2014 | 4 | 0.480 |
Why?
|
| Research | 1 | 2015 | 65 | 0.480 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 382 | 0.480 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2014 | 102 | 0.460 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2020 | 129 | 0.440 |
Why?
|
| Relaxin | 1 | 2013 | 1 | 0.430 |
Why?
|
| Endpoint Determination | 3 | 2017 | 10 | 0.420 |
Why?
|
| Emergency Service, Hospital | 3 | 2022 | 368 | 0.420 |
Why?
|
| Diltiazem | 1 | 2012 | 1 | 0.410 |
Why?
|
| Deoxycytidine | 1 | 2012 | 7 | 0.410 |
Why?
|
| Chest Pain | 1 | 2012 | 14 | 0.410 |
Why?
|
| Chronic Disease | 7 | 2021 | 428 | 0.410 |
Why?
|
| Fluorouracil | 1 | 2012 | 11 | 0.410 |
Why?
|
| Adult | 14 | 2022 | 7708 | 0.410 |
Why?
|
| Comorbidity | 9 | 2020 | 597 | 0.390 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 332 | 0.390 |
Why?
|
| Renal Insufficiency | 3 | 2019 | 13 | 0.380 |
Why?
|
| Analgesics, Opioid | 2 | 2018 | 246 | 0.380 |
Why?
|
| Electrocardiography | 5 | 2015 | 42 | 0.380 |
Why?
|
| Cardiovascular Agents | 4 | 2022 | 24 | 0.370 |
Why?
|
| Heart Function Tests | 1 | 2011 | 3 | 0.370 |
Why?
|
| Hospital Mortality | 10 | 2022 | 145 | 0.370 |
Why?
|
| Patient Selection | 4 | 2017 | 190 | 0.360 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 4 | 2021 | 10 | 0.360 |
Why?
|
| London | 2 | 2020 | 6 | 0.360 |
Why?
|
| Guideline Adherence | 4 | 2017 | 158 | 0.360 |
Why?
|
| Cohort Studies | 8 | 2022 | 2590 | 0.340 |
Why?
|
| Veterans | 2 | 2023 | 143 | 0.340 |
Why?
|
| Liraglutide | 2 | 2020 | 5 | 0.330 |
Why?
|
| Length of Stay | 5 | 2020 | 182 | 0.330 |
Why?
|
| Vascular Diseases | 2 | 2020 | 4 | 0.330 |
Why?
|
| Hemodynamics | 2 | 2020 | 7 | 0.320 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 2 | 2021 | 2 | 0.320 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2014 | 20 | 0.310 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2016 | 129 | 0.310 |
Why?
|
| Surveys and Questionnaires | 4 | 2017 | 1323 | 0.310 |
Why?
|
| Prescription Drug Misuse | 1 | 2018 | 11 | 0.300 |
Why?
|
| Disease Management | 3 | 2018 | 135 | 0.290 |
Why?
|
| Triglycerides | 2 | 2021 | 89 | 0.280 |
Why?
|
| Systole | 3 | 2017 | 22 | 0.280 |
Why?
|
| Drug Overdose | 1 | 2018 | 57 | 0.280 |
Why?
|
| Hematocrit | 2 | 2019 | 6 | 0.270 |
Why?
|
| Myocardial Infarction | 2 | 2020 | 238 | 0.270 |
Why?
|
| Marijuana Abuse | 1 | 2017 | 40 | 0.270 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 615 | 0.260 |
Why?
|
| Cardio-Renal Syndrome | 2 | 2019 | 2 | 0.260 |
Why?
|
| Marijuana Smoking | 1 | 2016 | 52 | 0.260 |
Why?
|
| Heart Transplantation | 2 | 2022 | 11 | 0.250 |
Why?
|
| Health Services | 1 | 2016 | 113 | 0.250 |
Why?
|
| Animals | 4 | 2014 | 262 | 0.240 |
Why?
|
| Biomarkers | 5 | 2020 | 310 | 0.240 |
Why?
|
| Incidence | 6 | 2020 | 1269 | 0.240 |
Why?
|
| Antihypertensive Agents | 3 | 2022 | 161 | 0.240 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2014 | 43 | 0.230 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2014 | 3 | 0.220 |
Why?
|
| Echocardiography | 2 | 2014 | 32 | 0.220 |
Why?
|
| Proportional Hazards Models | 6 | 2016 | 711 | 0.220 |
Why?
|
| Primary Prevention | 2 | 2020 | 73 | 0.210 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2022 | 2 | 0.210 |
Why?
|
| Aortic Valve Stenosis | 1 | 2022 | 3 | 0.210 |
Why?
|
| Atrial Fibrillation | 2 | 2016 | 170 | 0.210 |
Why?
|
| Coronary Angiography | 2 | 2014 | 21 | 0.210 |
Why?
|
| Opioid-Related Disorders | 2 | 2021 | 172 | 0.210 |
Why?
|
| Morbidity | 2 | 2020 | 59 | 0.200 |
Why?
|
| California | 5 | 2020 | 2328 | 0.200 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 49 | 0.200 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 56 | 0.200 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 391 | 0.200 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2022 | 3 | 0.200 |
Why?
|
| Natriuretic Peptides | 4 | 2014 | 5 | 0.200 |
Why?
|
| Acute Coronary Syndrome | 1 | 2022 | 18 | 0.200 |
Why?
|
| Nutritive Value | 1 | 2022 | 11 | 0.200 |
Why?
|
| Canada | 2 | 2021 | 66 | 0.190 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 115 | 0.190 |
Why?
|
| Attitude | 1 | 2022 | 30 | 0.190 |
Why?
|
| Amides | 2 | 2018 | 3 | 0.190 |
Why?
|
| Fumarates | 2 | 2018 | 4 | 0.190 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 107 | 0.190 |
Why?
|
| Phenotype | 2 | 2019 | 151 | 0.180 |
Why?
|
| Recurrence | 4 | 2020 | 189 | 0.180 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 20 | 0.180 |
Why?
|
| India | 1 | 2020 | 13 | 0.180 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2021 | 13 | 0.180 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2020 | 1 | 0.180 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2020 | 4 | 0.180 |
Why?
|
| Receptors, Angiotensin | 1 | 2020 | 3 | 0.180 |
Why?
|
| Coronary Artery Disease | 2 | 2012 | 134 | 0.180 |
Why?
|
| Biphenyl Compounds | 1 | 2020 | 10 | 0.180 |
Why?
|
| Death | 1 | 2020 | 10 | 0.180 |
Why?
|
| Opiate Substitution Treatment | 1 | 2021 | 46 | 0.180 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 50 | 0.180 |
Why?
|
| State Health Plans | 1 | 2010 | 35 | 0.180 |
Why?
|
| Analgesics | 1 | 2010 | 27 | 0.180 |
Why?
|
| Incretins | 1 | 2020 | 2 | 0.180 |
Why?
|
| Kidney Failure, Chronic | 1 | 2022 | 151 | 0.170 |
Why?
|
| Europe | 3 | 2017 | 42 | 0.170 |
Why?
|
| Longitudinal Studies | 5 | 2017 | 720 | 0.170 |
Why?
|
| Buprenorphine | 1 | 2021 | 48 | 0.170 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 455 | 0.170 |
Why?
|
| Transferrins | 1 | 2020 | 4 | 0.170 |
Why?
|
| Transferrin | 1 | 2020 | 5 | 0.170 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2020 | 2 | 0.170 |
Why?
|
| Ferritins | 1 | 2020 | 9 | 0.170 |
Why?
|
| Ventricular Fibrillation | 1 | 2020 | 4 | 0.170 |
Why?
|
| Cardiac Output, Low | 3 | 2018 | 3 | 0.170 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 6 | 0.170 |
Why?
|
| Sex Distribution | 3 | 2019 | 190 | 0.170 |
Why?
|
| Accelerometry | 1 | 2020 | 39 | 0.170 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2020 | 6 | 0.170 |
Why?
|
| Pain | 1 | 2010 | 79 | 0.170 |
Why?
|
| Galectin 3 | 1 | 2019 | 1 | 0.170 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2019 | 3 | 0.170 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2019 | 4 | 0.170 |
Why?
|
| Population Dynamics | 1 | 2019 | 6 | 0.170 |
Why?
|
| Kidney | 1 | 2020 | 53 | 0.170 |
Why?
|
| Hemoglobins | 1 | 2020 | 39 | 0.170 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 181 | 0.170 |
Why?
|
| Hemofiltration | 1 | 2019 | 1 | 0.170 |
Why?
|
| Hemoglobinometry | 1 | 2019 | 3 | 0.170 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2019 | 9 | 0.170 |
Why?
|
| Recovery of Function | 2 | 2016 | 27 | 0.170 |
Why?
|
| Pain, Postoperative | 2 | 2009 | 17 | 0.160 |
Why?
|
| Diet | 1 | 2022 | 366 | 0.160 |
Why?
|
| Heart Diseases | 1 | 2019 | 77 | 0.160 |
Why?
|
| Referral and Consultation | 1 | 2020 | 169 | 0.160 |
Why?
|
| Spironolactone | 1 | 2019 | 6 | 0.160 |
Why?
|
| Drug Resistance | 1 | 2019 | 32 | 0.160 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 417 | 0.160 |
Why?
|
| Lipids | 2 | 2019 | 82 | 0.160 |
Why?
|
| Intensive Care Units | 2 | 2021 | 105 | 0.160 |
Why?
|
| Tobacco Use Cessation | 1 | 2008 | 22 | 0.150 |
Why?
|
| North America | 2 | 2015 | 42 | 0.150 |
Why?
|
| Hypotension | 2 | 2020 | 5 | 0.150 |
Why?
|
| Adolescent | 7 | 2021 | 3690 | 0.150 |
Why?
|
| Drug Utilization | 2 | 2014 | 128 | 0.150 |
Why?
|
| France | 1 | 2018 | 12 | 0.150 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2018 | 42 | 0.150 |
Why?
|
| Age Distribution | 2 | 2019 | 246 | 0.150 |
Why?
|
| Depression | 2 | 2017 | 506 | 0.150 |
Why?
|
| Troponin | 1 | 2017 | 9 | 0.150 |
Why?
|
| Insurance Coverage | 1 | 2018 | 106 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 4 | 2021 | 86 | 0.140 |
Why?
|
| Ventricular Remodeling | 1 | 2017 | 6 | 0.140 |
Why?
|
| Substance Abuse Treatment Centers | 3 | 2008 | 75 | 0.140 |
Why?
|
| Health Policy | 1 | 2018 | 123 | 0.140 |
Why?
|
| Blood Glucose | 1 | 2019 | 349 | 0.140 |
Why?
|
| Self Care | 1 | 2008 | 163 | 0.140 |
Why?
|
| Urine | 1 | 2017 | 5 | 0.140 |
Why?
|
| Atrial Flutter | 2 | 2016 | 15 | 0.140 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2014 | 3 | 0.130 |
Why?
|
| Algorithms | 1 | 2018 | 239 | 0.130 |
Why?
|
| Activities of Daily Living | 1 | 2017 | 85 | 0.130 |
Why?
|
| Patient Dropouts | 1 | 2016 | 22 | 0.130 |
Why?
|
| Private Sector | 1 | 2006 | 15 | 0.130 |
Why?
|
| Vasopressins | 2 | 2012 | 5 | 0.130 |
Why?
|
| Pulmonary Edema | 1 | 2016 | 2 | 0.130 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2016 | 90 | 0.130 |
Why?
|
| HIV Infections | 1 | 2022 | 707 | 0.130 |
Why?
|
| Receptors, Vasopressin | 2 | 2012 | 2 | 0.130 |
Why?
|
| Mortality | 1 | 2016 | 118 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 487 | 0.120 |
Why?
|
| Reference Values | 1 | 2015 | 93 | 0.120 |
Why?
|
| Decision Making | 1 | 2016 | 184 | 0.120 |
Why?
|
| Primary Health Care | 1 | 2021 | 770 | 0.120 |
Why?
|
| Uric Acid | 1 | 2014 | 9 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 2014 | 54 | 0.120 |
Why?
|
| Syndrome | 2 | 2011 | 28 | 0.120 |
Why?
|
| Therapies, Investigational | 1 | 2014 | 1 | 0.120 |
Why?
|
| Outcome Assessment (Health Care) | 2 | 2013 | 228 | 0.110 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2014 | 2 | 0.110 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2014 | 4 | 0.110 |
Why?
|
| Vasodilator Agents | 1 | 2014 | 9 | 0.110 |
Why?
|
| Asia | 1 | 2014 | 15 | 0.110 |
Why?
|
| Magnesium | 1 | 2013 | 6 | 0.110 |
Why?
|
| Patient Compliance | 1 | 2006 | 301 | 0.110 |
Why?
|
| ROC Curve | 1 | 2013 | 77 | 0.110 |
Why?
|
| Liver Abscess | 1 | 2013 | 1 | 0.110 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2013 | 2 | 0.110 |
Why?
|
| Edema, Cardiac | 1 | 2013 | 1 | 0.110 |
Why?
|
| Respiratory Sounds | 1 | 2013 | 12 | 0.110 |
Why?
|
| Arginine Vasopressin | 1 | 2012 | 2 | 0.100 |
Why?
|
| Arrhythmia, Sinus | 1 | 2012 | 2 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2013 | 26 | 0.100 |
Why?
|
| Lymphocyte Count | 1 | 2012 | 1 | 0.100 |
Why?
|
| Ambulatory Care | 2 | 2012 | 247 | 0.100 |
Why?
|
| Fatigue | 1 | 2013 | 34 | 0.100 |
Why?
|
| Capecitabine | 1 | 2012 | 2 | 0.100 |
Why?
|
| Prodrugs | 1 | 2012 | 2 | 0.100 |
Why?
|
| Coronary Vasospasm | 1 | 2012 | 2 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2012 | 3 | 0.100 |
Why?
|
| Calcium Channel Blockers | 1 | 2012 | 14 | 0.100 |
Why?
|
| Anus Neoplasms | 1 | 2012 | 26 | 0.100 |
Why?
|
| Cholesterol | 1 | 2012 | 106 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 40 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2012 | 48 | 0.100 |
Why?
|
| Heart Failure, Systolic | 1 | 2012 | 4 | 0.100 |
Why?
|
| Neurotransmitter Agents | 1 | 2012 | 1 | 0.100 |
Why?
|
| Albumins | 1 | 2012 | 6 | 0.100 |
Why?
|
| Alkaline Phosphatase | 1 | 2012 | 7 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2014 | 194 | 0.100 |
Why?
|
| Obesity | 1 | 2018 | 842 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 55 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2012 | 159 | 0.100 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2011 | 1 | 0.100 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2011 | 2 | 0.100 |
Why?
|
| Liver Transplantation | 1 | 2011 | 7 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2012 | 237 | 0.090 |
Why?
|
| End Stage Liver Disease | 1 | 2011 | 9 | 0.090 |
Why?
|
| Diuresis | 1 | 2011 | 1 | 0.090 |
Why?
|
| Toxicity Tests | 1 | 2011 | 1 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 19 | 0.090 |
Why?
|
| Consensus | 1 | 2011 | 41 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 173 | 0.090 |
Why?
|
| Edema | 2 | 2020 | 5 | 0.090 |
Why?
|
| Romania | 3 | 2016 | 3 | 0.090 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 197 | 0.090 |
Why?
|
| Headache | 1 | 2010 | 14 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 211 | 0.090 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2009 | 2 | 0.080 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2020 | 22 | 0.080 |
Why?
|
| Analgesia, Epidural | 1 | 2009 | 4 | 0.080 |
Why?
|
| Demography | 1 | 2010 | 101 | 0.080 |
Why?
|
| Anesthesia, Caudal | 1 | 2009 | 1 | 0.080 |
Why?
|
| Groin | 1 | 2009 | 3 | 0.080 |
Why?
|
| Nerve Block | 1 | 2009 | 3 | 0.080 |
Why?
|
| Hernia, Inguinal | 1 | 2009 | 3 | 0.080 |
Why?
|
| Anxiety | 2 | 2016 | 151 | 0.080 |
Why?
|
| Age Factors | 3 | 2014 | 923 | 0.080 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2022 | 32 | 0.080 |
Why?
|
| Women's Health Services | 1 | 2008 | 20 | 0.080 |
Why?
|
| Electronic Health Records | 2 | 2018 | 698 | 0.080 |
Why?
|
| Clinical Protocols | 3 | 2014 | 43 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 100 | 0.070 |
Why?
|
| Kidney Function Tests | 2 | 2019 | 22 | 0.070 |
Why?
|
| Parents | 1 | 2009 | 297 | 0.070 |
Why?
|
| Creatinine | 2 | 2019 | 65 | 0.070 |
Why?
|
| Prevalence | 3 | 2015 | 888 | 0.060 |
Why?
|
| Sex Factors | 2 | 2014 | 644 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2017 | 673 | 0.060 |
Why?
|
| African Americans | 2 | 2020 | 472 | 0.060 |
Why?
|
| Injections, Intravenous | 2 | 2017 | 10 | 0.060 |
Why?
|
| Aortic Valve | 1 | 2022 | 4 | 0.050 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2022 | 1 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 12 | 0.050 |
Why?
|
| Shock, Cardiogenic | 1 | 2022 | 6 | 0.050 |
Why?
|
| Potassium | 1 | 2022 | 16 | 0.050 |
Why?
|
| Meals | 1 | 2022 | 7 | 0.050 |
Why?
|
| Child | 4 | 2010 | 2497 | 0.050 |
Why?
|
| Heart Rate | 1 | 2022 | 41 | 0.050 |
Why?
|
| Heart | 1 | 2022 | 13 | 0.050 |
Why?
|
| Aldosterone | 1 | 2022 | 2 | 0.050 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2023 | 128 | 0.050 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2022 | 9 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2022 | 181 | 0.050 |
Why?
|
| Hospitals | 1 | 2022 | 80 | 0.050 |
Why?
|
| Americas | 1 | 2021 | 2 | 0.050 |
Why?
|
| Nurse Administrators | 1 | 2021 | 7 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2021 | 49 | 0.050 |
Why?
|
| Mitral Valve | 1 | 2020 | 2 | 0.050 |
Why?
|
| Withholding Treatment | 1 | 2021 | 26 | 0.050 |
Why?
|
| Chicago | 2 | 2011 | 26 | 0.040 |
Why?
|
| Angiotensins | 1 | 2020 | 3 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2010 | 22 | 0.040 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2020 | 1 | 0.040 |
Why?
|
| Heart-Assist Devices | 1 | 2020 | 2 | 0.040 |
Why?
|
| Propensity Score | 1 | 2021 | 85 | 0.040 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2021 | 61 | 0.040 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2020 | 3 | 0.040 |
Why?
|
| Lung | 1 | 2020 | 62 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2011 | 114 | 0.040 |
Why?
|
| Electric Countershock | 1 | 2020 | 16 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2012 | 300 | 0.040 |
Why?
|
| Walk Test | 1 | 2019 | 5 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 35 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 34 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2019 | 34 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 20 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 93 | 0.040 |
Why?
|
| Washington | 1 | 2010 | 383 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2018 | 4 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2019 | 183 | 0.040 |
Why?
|
| Aging | 1 | 2019 | 163 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2008 | 125 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 315 | 0.040 |
Why?
|
| Social Environment | 1 | 2008 | 88 | 0.040 |
Why?
|
| Psychometrics | 1 | 2008 | 121 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 3 | 0.040 |
Why?
|
| Alberta | 1 | 2017 | 3 | 0.040 |
Why?
|
| Netherlands | 1 | 2017 | 7 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2020 | 229 | 0.040 |
Why?
|
| Italy | 1 | 2017 | 14 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 85 | 0.040 |
Why?
|
| Continental Population Groups | 1 | 2019 | 302 | 0.040 |
Why?
|
| Patient Safety | 1 | 2018 | 39 | 0.040 |
Why?
|
| Motivation | 1 | 2008 | 131 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2017 | 17 | 0.040 |
Why?
|
| Body Weight | 1 | 2018 | 224 | 0.040 |
Why?
|
| Medicaid | 1 | 2018 | 190 | 0.030 |
Why?
|
| Far East | 1 | 2016 | 6 | 0.030 |
Why?
|
| Asia, Southeastern | 1 | 2016 | 4 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 154 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2020 | 967 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 2016 | 8 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 232 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 272 | 0.030 |
Why?
|
| Triage | 1 | 2015 | 16 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2009 | 1424 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 569 | 0.030 |
Why?
|
| Managed Care Programs | 1 | 2006 | 325 | 0.030 |
Why?
|
| Young Adult | 1 | 2021 | 2464 | 0.030 |
Why?
|
| Logistic Models | 1 | 2016 | 928 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 2013 | 24 | 0.030 |
Why?
|
| Rome | 1 | 2013 | 1 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2013 | 13 | 0.030 |
Why?
|
| Hydrazones | 1 | 2013 | 1 | 0.030 |
Why?
|
| Xanthines | 1 | 2013 | 6 | 0.030 |
Why?
|
| Radiography | 1 | 2013 | 39 | 0.030 |
Why?
|
| Pyridines | 1 | 2013 | 9 | 0.030 |
Why?
|
| Pyridazines | 1 | 2013 | 6 | 0.030 |
Why?
|
| Europe, Eastern | 1 | 2012 | 1 | 0.030 |
Why?
|
| South America | 1 | 2012 | 4 | 0.030 |
Why?
|
| Internationality | 1 | 2012 | 14 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2013 | 216 | 0.030 |
Why?
|
| Ethnic Groups | 1 | 2006 | 485 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 755 | 0.020 |
Why?
|
| European Continental Ancestry Group | 1 | 2014 | 529 | 0.020 |
Why?
|
| Etiocholanolone | 1 | 2011 | 1 | 0.020 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2011 | 1 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 30 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2011 | 7 | 0.020 |
Why?
|
| Observer Variation | 1 | 2011 | 37 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 29 | 0.020 |
Why?
|
| Calcinosis | 1 | 2011 | 40 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 381 | 0.020 |
Why?
|
| Somatosensory Disorders | 1 | 2010 | 1 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2010 | 29 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2010 | 46 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2010 | 64 | 0.020 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2009 | 1 | 0.020 |
Why?
|
| Health Surveys | 1 | 2010 | 261 | 0.020 |
Why?
|
| Accreditation | 1 | 2008 | 5 | 0.020 |
Why?
|
| Child Care | 1 | 2008 | 11 | 0.020 |
Why?
|
| Ownership | 1 | 2008 | 15 | 0.020 |
Why?
|
| Methadone | 1 | 2008 | 10 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2008 | 230 | 0.020 |
Why?
|
| Infant | 1 | 2009 | 1198 | 0.020 |
Why?
|